Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia

Background & Aims— Georgia, with a high prevalence of HCV infection, launched the world’s first national hepatitis C elimination program in April 2015. A key strategy is the identification, treatment, and cure of the estimated 150,000 HCV-infected people living in the country. We report on progress and key challenges from Georgia’s experience. Methods— We constructed a care cascade by analyzing linked data from the national hepatitis C screening registry and treatment databases during 2015–2018. We assessed the impact of reflex hepatitis C core antigen (HCVcAg) testing on rates of viremia testing and treatment initiation (i.e. linkage to care). Results— As of December 31, 2018, 1,101,530 adults (39.6% of the adult population) were screened for HCV antibody, of whom 98,430 (8.9%) tested positive. Of the individuals who tested positive, 78,484 (79.7%) received viremia testing, of whom 66,916 (85.3%) tested positive for active HCV infection. A total of 52,576 people with active HCV infection initiated treatment and 48,879 completed their course of treatment. Of the 35,035 who were tested for cure (i.e., sustained virologic response [SVR]), 34,513 (98.5%) achieved SVR. Reflex HCVcAg testing, implemented in March 2018, increased rates of monthly viremia testing by 97.5% among those who screened positive for anti-HCV, however, rates of treatment initiation decreased by 60.7% among diagnosed viremic patients. Conclusions— Over one-third of people living with HCV in Georgia have been detected and linked to care and treatment, however, identification and linkage to care of the remaining individuals with HCV infection is challenging. Novel interventions, such as reflex testing with HCVcAg, can improve rates of viremia testing, but may result in unintended consequences, such as decreased rates of treatment initiation. Linked data systems allow for regular review of the care cascade, allowing for identification of deficiencies and development of corrective actions. This report describes progress inGeorgia’s hepatitis C elimination programand highlights efforts to promote hepatitis C virus screening and treatment initiation on a national scale. Georgia has made progress towards eliminating hepatitis C, treating over 50,000 people, approximately one-third of the number infected, and achieving cure for 98.5% of those tested. However, identifying infected individuals and linking them to care remains challenging. Novel approaches to increase diagnostic testing can have unintended consequences further down the care cascade.

[1]  Josephine G. Walker,et al.  Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study , 2019, The Lancet. Global health.

[2]  J. Lazarus,et al.  Excellence in Viral Hepatitis Elimination - Lessons from Georgia. , 2019, Journal of hepatology.

[3]  Sanjeev Arora,et al.  Three years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 - March 2018. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Gamkrelidze,et al.  Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs — Georgia, 2018 , 2019, MMWR. Morbidity and mortality weekly report.

[5]  A. Gamkrelidze,et al.  Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination , 2019, BMC Public Health.

[6]  M. Hellard,et al.  Treatment access is only the first step to hepatitis C elimination: experience of universal anti‐viral treatment access in Australia , 2019, Alimentary pharmacology & therapeutics.

[7]  R. Peeling,et al.  Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. , 2019, The lancet. Gastroenterology & hepatology.

[8]  J. Mukherjee,et al.  Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. , 2019, The lancet. Gastroenterology & hepatology.

[9]  J. Ward,et al.  The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals , 2019, Journal of virus eradication.

[10]  I. Waked,et al.  One step closer to elimination of hepatitis C in Egypt. , 2018, The lancet. Gastroenterology & hepatology.

[11]  H. Masur,et al.  Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. , 2017, Annals of internal medicine.

[12]  J. Ward,et al.  The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination — Georgia, 2015–2016 , 2017, MMWR. Morbidity and mortality weekly report.

[13]  A. Gamkrelidze,et al.  HCV elimination — lessons learned from a small Eurasian country, Georgia , 2017, Nature Reviews Gastroenterology &Hepatology.

[14]  J. Ward,et al.  National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. , 2016, MMWR. Morbidity and mortality weekly report.

[15]  J. M. Freiman,et al.  Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection , 2016, Annals of Internal Medicine.

[16]  J. Ward,et al.  Launch of a Nationwide Hepatitis C Elimination Program — Georgia, April 2015 , 2015, MMWR. Morbidity and mortality weekly report.